Low C L, McGoldrick M D, Bailie G R
Albany College of Pharmacy, NY 12208, USA.
Clin Nephrol. 1997 Jan;47(1):60-2.
We report the first case of the use of ibuprofen for the management of steroid-resistant nephrotic syndrome. A 41 year-old man with nephrotic syndrome, secondary to focal segmental glomerulosclerosis, had persistent nephrotic range proteinuria despite aggressive treatment with steroids and cyclophosphamide. His steroid-resistant nephrotic syndrome resolved rapidly when he was serendipituously started on ibuprofen for the treatment of pericarditis. His proteinuria remained low at about 0.5 g/day over the next two years of treatment with ibuprofen and without any increase in his serum creatinine. He did not receive any ACE inhibitor or calcium channel blocker. An attempt to discontinue ibuprofen resulted in the relapse of his nephrotic syndrome. Upon restarting ibuprofen, his proteinuria decreased to less than 0.5 g/day again. We conclude that ibuprofen has been effective and safe for the management of nephrotic syndrome in this patient. However, careful monitoring is prudent to assess the potential adverse effects of ibuprofen on renal function with prolonged use.
我们报告了首例使用布洛芬治疗激素抵抗型肾病综合征的病例。一名41岁患有肾病综合征的男性,继发于局灶节段性肾小球硬化,尽管接受了激素和环磷酰胺的积极治疗,但仍持续存在肾病范围的蛋白尿。当他因心包炎意外开始使用布洛芬治疗时,他的激素抵抗型肾病综合征迅速得到缓解。在接下来使用布洛芬治疗的两年里,他的蛋白尿一直维持在较低水平,约为0.5克/天,且血清肌酐没有任何升高。他未接受任何血管紧张素转换酶抑制剂或钙通道阻滞剂。尝试停用布洛芬导致他的肾病综合征复发。重新开始使用布洛芬后,他的蛋白尿再次降至低于0.5克/天。我们得出结论,布洛芬对该患者肾病综合征的治疗有效且安全。然而,谨慎监测以评估长期使用布洛芬对肾功能的潜在不良反应是明智的。